Affinity and Dealroom.co Partner to Bring Global Relationship and Predictive Intelligence to Dealmakers
Affinity, the relationship intelligence platform for dealmakers, and Dealroom.co, a global provider of data and intelligence on startups and tech ecosystems, today announced a partnership to provide the most powerful combination of predictive intelligence and relationship intelligence for dealmakers. The partnership will provide Affinity clients with additional data intelligence for over 1.7 million startups and 2.1 million organizations globally. Joint clients of both Affinity and Dealroom.co will be able to access even more insights through additional data columns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005042/en/
“Our clients use Affinity to find, manage, and close the most important deals, and using organizational data insights helps them to target the right organizations is a critical part of their success,“ said Ray Zhou, CEO of Affinity. “Adding Dealroom.co’s predictive intelligence data to Affinity will ensure they can do that faster and with more confidence than ever before. ”
Affinity’s platform will integrate Dealroom.co’s wide range of critical data to enrich organizational records with additional firmographic data, predictive data insights, and leading market momentum indicators (such as social engagement). This will enable investors, M&A professionals, and other dealmakers to deliver the most complete understanding of deal opportunities and reduce the time they spend deciding which deals or organizations to focus on. Joint clients of both organizations will also receive access to additional Dealroom.co data columns in Affinity, including app downloads, website traffic, and founders’ history of success, further streamlining organizational intelligence gathering.
“As the intelligence layer for tech ecosystems, we help clients discover the world’s most promising companies through predictive intelligence,” said Yoram Wijngaarde, Founder and CEO at Dealroom.co. “This partnership puts this timely data into the hands of more investors around the world. We're excited to work with Affinity to provide investors with the data they need to be successful.”
Learn more about the power of Affinity and Dealroom.co’s data in the recently released joint report “Relationship Intelligence Benchmark Report: European Unicorn Edition,” and watch the “European Unicorn Trends: How to Make Unicorn Hunting More Predictable” webinar which brings industry experts together to discuss the trends impacting dealmakers as well as the role relationship intelligence plays in the evolving market landscape.
Across the Affinity platform, over 500,000 new introductions are made and 450,000 deals are managed per month, helping dealmakers to find, manage, and close more deals. Currently, Affinity serves over 2,000 clients worldwide, including 500 in Europe where many already use Dealroom.co data in their dealmaking process. By capturing the exhaust of relationship interactions—over 18 trillion emails and 213 million calendar invites to date—Affinity automates the creation of contact and company records and tracks activity saving over 220 hours every year in data entry work.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations around the world. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
About Dealroom.co
Dealroom.co is the foremost data provider on startups, innovation, high-growth companies,
ecosystems, and emerging tech. Founded in Amsterdam in 2013, Dealroom.co works with many of the world’s most prominent investors, entrepreneurs, and government organizations to provide transparency, analysis, and insights on venture capital activity. Dealroom.co mission is to accelerate entrepreneurship and innovation through data, insights, and predictive intelligence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005042/en/
Contact information
Bospar
Sana Javaid
PRforAffinity@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom